La Trogocytose Est-elle un Marqueur prédictif de la réponse Aux Cellules CAR-T Dans Les Lymphomes Diffus à Grandes Cellules B ?
CAR-T cell therapy has improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL R/R). However, only 65% of patients achieve a complete metabolic response after this treatment. To date, there is no predictive test for therapeutic response after injection of CAR-T cells. Recent studies have shown that the level of trogocytosis by immune cells correlates with the persistence of tumor cells in patients with hematological malignancies. Our main objective is to identify a phenotypic signature of trogocytosis predictive of therapeutic response 6 months after injection of CAR-T cells for DLBCL.
• For patients
‣ Patient who has given free and informed consent in writing for inclusion in the non-interventional CART-BANK protocol, and orally for the CARTROG protocol,
⁃ Patients over 18 years of age at the time of inclusion,
⁃ Diagnosis of LDGCB,
⁃ Decision to treat with anti-CD19 CAR-T cells,
⁃ Patient affiliated to or benefiting from a social security scheme.
• For healthy volunteers:
‣ Given free and informed oral consent for inclusion in the CARTROG protocol,
⁃ Donor between 18 and 70 years of age at the time of inclusion,
⁃ No history of solid cancer or hematological malignancy,
⁃ No known chronic pathology (e.g. hypertension, diabetes, etc.) and no daily treatment,
⁃ No surgical treatment within the last 6 months.